Long-term efficacy of therapeutic drug monitoring-guided optimization of ustekinumab maintenance therapy for Crohn’s disease patients
Uložené v:
| Názov: | Long-term efficacy of therapeutic drug monitoring-guided optimization of ustekinumab maintenance therapy for Crohn’s disease patients |
|---|---|
| Autori: | Haixia Ren, Juan Su, Anning Yin, Xinsheng Gao, Wei Wang, Jiao Li, Jian Kang, Jing Wang, Qian Zhou, Jing An, Zhishun Tang, Xinxin Wang, Huipeng Wan, Wei Chen, Pengbo Wu, Ping An |
| Zdroj: | Scientific Reports, Vol 15, Iss 1, Pp 1-10 (2025) |
| Informácie o vydavateľovi: | Nature Portfolio, 2025. |
| Rok vydania: | 2025 |
| Zbierka: | LCC:Medicine LCC:Science |
| Predmety: | Medicine, Science |
| Popis: | Abstract Long-term remission in Crohn’s disease (CD) remains challenging. While ustekinumab effectively induces remission, strategies to enhance its maintenance efficacy are urgently needed. This study evaluated therapeutic drug monitoring (TDM)-guided ustekinumab optimization for sustained CD management. A retrospective observational study was conducted involving 158 patients [TDM: n = 87, age(16 39), male = 64; Non-TDM: n = 71, age(16–40), male = 57] with moderate-to-severe CD who achieved clinical remission following ustekinumab therapy, between October 2020 and November 2024, sourced from three inflammatory bowel disease centers. All patients received 8 weekly ustekinumab maintenance treatment with or without therapeutic drug monitoring (TDM)-guided optimization. The clinical outcomes and disease relapse were evaluated at year 1 and 2. The non-TDM group had a slightly higher endoscopic response and mucosal healing rate at baseline, there were no statistically significant differences between two cohorts at baseline with respect to demographic and clinical characteristics. In this multicenter retrospective study of 158 CD patients in clinical remission, TDM-guided dosing (n = 87) significantly improved 1 year (83.9% vs. 70.4%, p = 0.042) and 2 year remission rates (71.3% vs. 46.5%, p = 0.002) compared to standard therapy (n = 71). Subgroup analyses confirmed benefits in endoscopic responders and mucosal healing cohorts. TDM patients exhibited higher ustekinumab trough levels (3.00 vs. 1.46 μg/mL at year 1, p |
| Druh dokumentu: | article |
| Popis súboru: | electronic resource |
| Jazyk: | English |
| ISSN: | 2045-2322 |
| Relation: | https://doaj.org/toc/2045-2322 |
| DOI: | 10.1038/s41598-025-09802-5 |
| Prístupová URL adresa: | https://doaj.org/article/c0228f4a5e1f41d5ba1b6147a52f9ce7 |
| Prístupové číslo: | edsdoj.0228f4a5e1f41d5ba1b6147a52f9ce7 |
| Databáza: | Directory of Open Access Journals |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Abstract Long-term remission in Crohn’s disease (CD) remains challenging. While ustekinumab effectively induces remission, strategies to enhance its maintenance efficacy are urgently needed. This study evaluated therapeutic drug monitoring (TDM)-guided ustekinumab optimization for sustained CD management. A retrospective observational study was conducted involving 158 patients [TDM: n = 87, age(16 39), male = 64; Non-TDM: n = 71, age(16–40), male = 57] with moderate-to-severe CD who achieved clinical remission following ustekinumab therapy, between October 2020 and November 2024, sourced from three inflammatory bowel disease centers. All patients received 8 weekly ustekinumab maintenance treatment with or without therapeutic drug monitoring (TDM)-guided optimization. The clinical outcomes and disease relapse were evaluated at year 1 and 2. The non-TDM group had a slightly higher endoscopic response and mucosal healing rate at baseline, there were no statistically significant differences between two cohorts at baseline with respect to demographic and clinical characteristics. In this multicenter retrospective study of 158 CD patients in clinical remission, TDM-guided dosing (n = 87) significantly improved 1 year (83.9% vs. 70.4%, p = 0.042) and 2 year remission rates (71.3% vs. 46.5%, p = 0.002) compared to standard therapy (n = 71). Subgroup analyses confirmed benefits in endoscopic responders and mucosal healing cohorts. TDM patients exhibited higher ustekinumab trough levels (3.00 vs. 1.46 μg/mL at year 1, p |
|---|---|
| ISSN: | 20452322 |
| DOI: | 10.1038/s41598-025-09802-5 |